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Summary Eight anthracycline analogs that have been shown to modulate multidrug resistance (Friche et al.,
Biochem. Pharmacol., 39, 1721-1726; 1990) were tested for their inhibitory effect on the photolabelling of
P-glycoprotein. We photoaffinity labelled P-glycoprotein in daunorubicin (DNR) resistant Ehrlich ascites
tumour cells (EHR2/DNR + ) with a ['25I]iodinated Bolton-Hunter derivative of daunorubicin ([1251]iodomycin)
and with [3H]azidopine. The photolabelling of P-glycoprotein by ['251I]iodomycin was inhibited more than 50%
by 10iM (1000-fold molar excess) of DNR (52%), N,N-dibenzyl-DNR (52%), and N-benzyladriamycin-14-
valerate (AD-198) (85%). Vincristine at 10JiM inhibited ['251]iodomycin labelling of P-glycoprotein by 95%.
Thus vincristine was more potent than any of the eight anthracyclines tested, despite its relatively low
lipophilicity. Increasing the concentration of DNR, AD-198 and N,N-dibenzyl-DNR to 40 iM resulted in 90,
99.5 and 99.5% inhibition of P-glycoprotein labelling by ['251I]iodomycin, respectively. In comparison with the
other anthracycline analogs, N,N-dibenzyl-DNR and Ad-198 were also found to exert the greatest inhibition
of [3H]azidopine labelling of P-glycoprotein (about 90% at 100-fold molar excess). The solvents Cremophor
EL and Tween 80 (30 jig ml-'; 0.003% v/v), which are modulators of multidrug resistance in EHR2/DNR +
cells, also inhibited ['25I]iodomycin labelling >90%. We showed earlier that there is a correlation between the
lipid solubility within the anthracycline group of MDR-associated drugs and their ability to enhance DNR
accumulation in EHR2/DNR + cells but a corresponding correlation to lipophilicity when it comes to the
inhibitory effect on the specific photolabelling of Pgp ligand binding sites could not be demonstrated. Neither
could a correlation between the modulating effect of the analogs on DNR accumulation and inhibition on the
labelling of Pgp be demonstrated. With increasing lipophilicity of the analogs it seems that the chemical
structure plays a lesser role, and the degree of lipophilicity becomes a more important feature.
Anthracyclines are among the most valuable cytostatic agents
in clinical use. Their usefulness is, however, limited by the
occurrence of tumour cells with the multidrug resistance
(MDR) phenotype (Beck, 1987; Bliek & Borst, 1989;
Endicott & Ling, 1989; Kaye & Merry, 1985; Moscow &
Cowan, 1988). MDR cells have an enhanced amount of a
150- 170 kDa plasma membrane glycoprotein, P-glycoprotein
(Pgp) (Kartner et al., 1983 and 1985; Cornwell et al., 1986;
Bradley et al., 1988; Beck, 1991a; Roninson, 1991), that may
function as a low-specificity transport protein to facilitate the
outward transport of cytotoxic agents including the
anthracyclines. Thus, increased drug efflux and therefore
decreased accumulation is seen in MDR cells not only to the
drug for which resistance is developed but also to a wide
spectrum of chemically unrelated cytostatics (Bradley et al.,
1988; Fojo et al., 1985). A variety of compounds have been
shown to bind to Pgp: Vinca alkaloids, progesterone,
azidopine, verapamil analogs, prazosin, iodomycin, and N-
azido-benzoyldaunomycin (recently reviewed by Beck &
Qian, 1992). We have reported earlier, that several anthra-
cycline analogs in vitro were able to modulate DNR-
resistance in Ehrlich ascites tumour cells by enhancing the
drug accumulation (Friche et al., 1990a). The aim of this
study was to examine these analogs for their ability to com-
pete for ligand binding to Pgp and thus service as inhibitors
for the outward drug transport system in MDR cells.
Anthracycline inter-actions with Pgp were assessed using the
specific photolabelling of the protein with [251I]iodomycin, a
['251]iodinated Bolton-Hunter derivative of DNR (Busche et
al., 1989a) and with [3H]azidopine ([3H]AZP) which
photolabels Pgp in plasma membrane vesicles from EHR2/
DNR + cells (Sehested et al., 1990) as well as in whole cells
(Safa et al., 1987; Friche et al., 1990c). Further, we have
studied the inhibitory effects of AZP, vincristine, and




Duanorubicin (DNR); AdriamycinR (Doxorubicin/HCl,
DOX); 4'-deoxy-4'-iododoxorubicin (DIDOX); and 4-
demethoxy-DNR were kindly supplied from Farmitalia,
Carlo Erba (Milan, Italy). N,N-dibenzyl-DNR was a gift
from Dr Nicholas Bachur, (Baltimore, MD) and N-
benzyladriamycin-14-valerate (AD 198) a gift from Professor
M. Israel (Memphis, TN). Mitoxantrone was purchased from
Lederle (New Jersey, USA), Aclacinomycin A from Lund-
beck & Co A/S (Copenhagen, Denmark), OncovinR
(Vincristine/HCl, VCR) from Eli Lilly Deutschland GMBH
(Giessen, Germany), Cremophor EL from BASF
Aktiengesellschaft (Ludwigshafen, Germany), and Tween 80
from the Sigma Chemical Co. (St. Louis, MO). ['251]-Bolton-
Hunter reagent (2000 Ci mmol 1), [3H]AZP (42 Ci mmol-')
and non-radioactive AZP were purchased from Amersham
International (Amersham, UK). All other chemicals were of
analytical grade. Organic solvents were distilled prior to use.
Triethylamine was distilled over ninhydrin and anhydrous
methanol was stored over molecular sieve (3 A).
Tumour cells
Cells were either the wild-type Ehrlich ascites tumor line
(EHR2) or the corresponding DNR-resistant line (EHR2/
DNR + ) (Dan0, 1971) displaying both the MDR phenotype
(Sehested et al., 1990) and as recently shown, decreased
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amount of topoisomerase II (Friche et al., 1991). Resistance
to DNR was developed and maintained in vivo in mice as
previously described in detail (Dan0, 1971). In vivo the subline
is at least 16-fold resistant to DNR (Friche et al., 1987) and
in vitro in a clonogenic assay about 80-fold resistant (Friche
et al., 1990b). No drug treatment was given to the resistant
tumour during the last passage before an in vitro experiment.
Synthesis of[I251]iodomycin
A modification of the procedure of Busche et al. (1989a) was
used for the synthesis of ['25I]iodomycin (Figure 1). DNR
(80 nmol) in 100 jl of dry methanol containing 1 mM tri-
ethylamine was reacted with a solution of 0.5 nmol (1 mCi)
monoiodinated Bolton-Hunter reagent (N-succinimidyl-3-(4-
hydroxy, 5-(['251I]iodophenyl)propionate) in 200 1I of dry
benzene containing 0.2% dimethylformamide. After 2 h at
room temperature, the product was purified by TLC on
precoated 0.25 mm silica gel 60 plates (Merck, Germany)
with the solvent system ethyl acetate/diethyl ether (2:1, v/v,
Rf 0.12), and extracted from the silica by ethanol (2 x 1 ml).
The solvent was evaporated under a stream of nitrogen to a
final volume of about 200 jAl. The radiochemical yields on the
basis of Bolton-Hunter reagent were typically 50-60%.
Drug accumulation and lipophilicity
Drug accumulation experiments with EHR2 and EHR2/
DNR + cells and determination of drug lipophilicity by
octanol/water partitioning were carried out as described
previously (Friche et al., 1990 a,b,c).
Photolabelling ofPgp by ['25lJiodomycin and [3H]AZP
[1251I]iodomycin and [3H]AZP in ethanolic solutions were
added at a final concentration of 1OnM and 0.4ljM, respec-
tively (1% v/v final ethanol) to cell suspensions (2 x 106
cells ml-') in phosphate buffer (Friche et al., 1990a) contain-
ing 10mM glucose. Aliquots (300JLI) were transferred to a
Micro Well plate (Nunc, Roskilde, Denmark), and various
concentrations of anthracyclines, or MDR modulators were
added (see Tables I and II). The samples were incubated for
30 min at 37°C, before irradiation under 254 nm UV light for
20min. The cells were then transferred to Eppendrof tubes
and centrifuged for 2 min at 10,000 rpm. Fifty jil of 1% NP
40 were added to dissolve the cell pellets and after 10min,
the suspensions were centrifuged for 5 min at 15,000 rpm.
The resulting supernatants were transferred to new tubes and
10 jAl of SDS (10%) and 10lA of bromphenolblue in 50%
glycerol were added before analysis by SDS PAGE using
10% gels. Control experiments confirmed complete extraction
of Pgp from the cells by this procedure. Following electro-
Table II Per cent inhibition of ['251]iodomycin photolabelling by
Pgp by various MDR modulators
O JPM S M 10 1M O/W
Vincristine 0 53.1 78.6 94.3 1.98
O I 1M S M 10J M 0/W
Azidopine 0 6.7 50.0 67.9 27.61
O 1 Jgml-' JOjgml 30pjgmlm'
Cremophor EL 0 28.6 71.5 92.8
Tween 80 0 73.4 91.2 97.7
Experimental details as in Table I, but with varying concentrations
of modulators as indicated. Results are expressed as per cent of the
control without added modulator. The number of experiments varies
from 2-5 for the different drugs with a variation- 10%.
phoresis, the gels were stained for protein with Coomassie
Brilliant blue. In experiments with [3H]AZP, the gels were
prepared for fluorography in Amplify" (Amersham Interna-
tional, UK). Fluorographs were obtained with Kodak X-
Omat film (Eastman Kodak Co., Rochester, NY) exposed for
4 days at - 80°C. Quantitation of ['251I]iodomycin and
[3H]AZP labelling of Pgp was carried out by photodensito-
metry of the fluorographs using a LKB UltraScan Laser
Densitometer (Sweden).
Results
Inhibitory effect ofDNR, DOX and N,N-dibenzyl-DNR on
['25I]iodomycin photolabelling ofPgp
Photolabelling of proteins in intact EHR2 and Pgp-MDR
EHR2/DNR + cells with ['251]iodomycin and [3H]AZP and
the effects of DNR, DOX and N,N-dibenzyl-DNR on this
labelling are shown in Figure 2. In EHR2/DNR + cells, a
distinct Mr 170,000 band at the position of Pgp was labelled
with 10 nM ['25I]iodomycin (lane 2) and with 0.4jAM [3H]-AZP
(lane 12). No labelling in this region was seen in the EHR2
cells (lane 1). The specific labelling of Pgp by [125lJiodomycin
was inhibited in a dose-dependent manner by the anthra-
cyclines, when they were preincubated with the cells for
30min, at which time steady-state accumulation was reached
for all the anthracyclines. Ten,AM (1000-fold molar excess)
DNR or N,N-dibenzyl-DNR inhibited labelling by about
50% (lanes 3 and 9), while DOX at this concentration did
not cause significant inhibition of labelling (lane 6). At
20JLM, 83%, 0%, and 97% inhibition was observed by DNR,
DOX, and N,N-dibenzyl-DNR, respectively (lanes 10, 7 and
4). A further increase in DNR and N,N-dibenzyl-DNR con-
centration to 40 JM resulted in a nearly total inhibition of
Table I Percent inhibitory effect of anthracyclines on ['25I]iodomycin and ([3H]AZP)
photolabelling of Pgp in EHR2/DNR + cells and their linid solubilitv
Drug 10jAm 20gm 40gM 01/W
Doxorubicin 0 (0). 0 (10.5) 16.8 (11.0) 1.22
DIDOX 20.6 (0) 17.5 (0) 22.5 (19.7) 14.51
4-demethoxy-daunorubicin 35.9 ( 1.5) 52.2 ( 3.6) 58.3 (19.8) 13.08
Mitoxantrone 42.9 ( 7.5) 56.9 (15.6) 58.8 (19.5) 5.06
Aclacinomycin A 22.6 (65.3) 52.0 (74.7) 75.3 (85.7) >200
Daunorubicin 52.5 ( 8.0) 82.7 (33.2) 90.6 (50.0) 7.85
AD-198 85.0 (74.1) 95.8 (81.7) >99 (90.9) >200
N,N,-dibenzyl-daunorubicin 52.4 (75.2) 97.3 (87.1) >99 (90.5) >200
'Numbers in parentheses represent inhibition of [3H]AZP binding. Numbers not in
parentheses represent inhibition of ['251]iodomycin binding.
Suspensions of EHR2/DNR + cells (2 x 106cells ml-' were incubated for 30min at
37°C with either iodomycin (10 nM) or [3H]AZP (0.4jAM) in the absence (control) and
in the presence of various concentrations of anthracyclines (10-40jAM). See 'Materials
and methods' for details. Lipid solubility (O/W) of the anthracyclines was determined
by measuring the partition of the drugs between an aqueous phase and octanol as
described in Friche et al. (1990a). Part of the lipid solubility data is published in
Friche et al. (1990a). Results are expressed as per cent of the control without added
anthracycline.228 E. FRICHE et al.
labelling (90 and >99% respectively) (lanes 11 and 5). Still,
DOX had little inhibitory effect (17%, lane 8).
Relationship between anthracycline lipophilicity and inhibition
ofPgpphotolabelling
Table I lists the anthracycline analogs and shows their
inhibitory effect on ['25I]iodomycin and [3H]AZP (numbers in
brackets) labelling of Pgp. Included in Table I is also the
lipid solubility of these analogs measured as the octanol/
water partition coefficient at pH 7.45. It is seen that no
simple relationship between lipophilicity of the anthracycline
analogs and their capacity to inhibit the photolabelling of
Pgp could be demonstrated.
Relationship between modulating effect ofanthracyclines on
DNR accumulation and inhibition ofPgpphotolabelling
We have shown earlier that some anthracyclines were
modulators of DNR resistance (Friche et al., 1990a).
Therefore a possible coherence between modulating effect of
the anthracyclines on DNR accumulation and inhibition of
Pgp photolabelling was examined. A correlation between the
influence of the analogs on steady-state accumulation of
DNR and their inhibitory effect on labelling of Pgp by
['25I]iodomycin or [3H]AZP could not be demonstrated
(Figure 3). Nonetheless, the two highly lipophilic analogs,
Aclacinomycin A and N,N-dibenzyl-DNR, which were the
most effective to inhibit labelling of Pgp also did increase
accumulation of DNR the most at equimolar concentrations
( = S AM).
Inhibitory effect of VCR, AZP anddetergents on
['25I]iodomycin photolabelling ofPgp
We also examined the ability of other compounds to inhibit
['25I]iodomycin labelling of Pgp (Table II). VCR (1 jAM), to
EHR2
I I I
Figure 1 Structure of ['25I]iodomycin.
which EHR2/DNR + cells are cross-resistant, inhibited the
labelling by about 50%, and 10 t4M VCR almost completely
blocked this labelling. AZP hardly inhibited ['25liodomycin
labelling of Pgp at 1 jiM, while 5ijM resulted in a 50%
inhibition. Finally, the detergents Cremophor EL and Tween
80, both ofwhich have been shown to reverse drug-resistance
in EHR2/DNR + cells at 30 jg ml-' (0.003% v/v) (Friche et
al., 1990c), also inhibited photolabelling of Pgp by
[1251]iodomycin by >90% when present in the reaction mix-
ture at this concentration.
Discussion
Overexpression ofPgp (Riordan & Ling, 1985) and inhibition
of its function by several classes of membrane-active drugs
EHR2/DNR +-
[1 2511-BH-DNR [3H] AZP
I I- ---
1 2 3 4 5 6 8 9 10 11 12
I J I I I J
N,N-dibenyzyl- DOX DNR
DNR
Figure 2 Effects of DNR, DOX and N,N-dibenzyl-DNR on ['25I]iodomycin photolabelling of Pgp in EHR2/DNR + cells.
EHR2/DNR + cells (2 x 106 cells/lane) were labelled with ['25Iiodomycin (10 nM) and separation of total cell protein was by
SDS-PAGE as described in 'Materials and methods'. The position of Pgp in the gel is indicated as 170 kDa. Photolabelling was
carried out in the absence of drugs (lane 2) and in the presence of 10, 20 or 40 juM of either DNR (lanes 9-11), DOX (lanes 6-8),
or N,N-dibenzyl-DNR (lanes 3-5) preincubated with the cells for 30 min. Lane I shows EHR2 as negative control, and lane 12,
EHR2/DNR + cells photolabelled with [3H]AZP (0.4gM). The fluorogram was developed with a film exposure of 4 days. The
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Figure 3 The modulating effect of anthracyclines on steady-state accumulation of 5 tLM DNR in EHR2/DNR + cells plotted
against the per cent inhibition of photolabelling of Pgp at 40 LM antracycline concentration.
(Beck, 1991b) are characteristic features of the MDR
phenotype. Since various anthracycline analogs (Friche et al.,
1990a) and VCR (Inaba & Nagashima, 1986) can enhance
DNR accumulation in MDR cells, examination of these
drugs for their binding to Pgp was appropriate.
The present study demonstrates the ['25I]iodomycin
photolabels Pgp in our MDR EHR2/DNR + cells and that
this labelling can be inhibited in a concentration dependent
manner by several anthracycline analogs as well as by other
compounds known to modulate MDR. In drug accumulation
experiments, we found a near 5-fold reduced steady-state
accumulation of ['251]iodomycin in EHR2/DNR + relative to
EHR2 (42 and 207 fmol 10-6 cells, respectively), in agree-
ment with the data of Busche et al., (1989a) indicating that
iodomycin itself is transported by the MDR efflux process.
Zamora et al., 1988 and Pearce et al., 1989 have shown that
some ideal structures have to be present to fulfill the
demands for a good modulator: at least two planar aromatic
rings, a basic nitrogen that would be positively charged at
physiological pH and some lipophilicity. The tested anthra-
cycline analogs fulfill all these demands and yet their effects
as modulators are very varying. DNR had a significant effect
in inhibiting photolabelling of Pgp by its N-acylated analog
['25I]iodomycin (90% at 40gM), whereas it was only about
half as effective in inhibiting [3H]AZP labelling at this con-
centration. The very lipophilic N,N-dibenzyl-DNR and AD-
198 were the analogs that, on a molar basis, caused the most
pronounced inhibition of both ['25I]iodomycin and [3H]AZP
labelling ofPgp. These analogs are also the ones to which the
cells show a low degree of resistance. DOX was found to
have hardly any inhibitory effect neither on ['25I]iodomycin
nor on [3H]AZP labelling (10-17% at 40 1M). This is consis-
tent with our previous finding (Friche et al., 1990a) that
DOX does not increase accumulation of DNR by inhibiting
its outward transport. Safa et al. (1987) also found that DOX
only slightly inhibited [3H]AZP labelling of Pgp (19%). A
proposal for the moderate effect of DOX on Pgp photolabel-
ling might be its low lipophilicity. This is, however, not in
accordance with the highly effective VCR, which shows very
low lipophilicity too, why one could think of some sterical
rotation. DIDOX, which only differs from DOX by substitu-
tion of the 4'-hydroxyl group in the amino sugar with iodine,
also did not have a marked inhibitory effect on [l25I]_
iodomycin labelling of Pgp, despite being more lipophilic
than both DNR and DOX (Friche et al., 1990b). This is in
agreement with the finding that DIDOX, which accumulated
to the same degree in both DNR-resistant and DNR-
sensitive Ehrlich cells, did not increase DNR accumulation
and thus does not appear to be a substrate for Pgp (Friche et
al., 1990b; Arcamone, 1985). Similar results were obtained in
the labelling experiments with [3H]AZP. One explanation
might be that the nitrogen atom in DIDOX due to the close
position to iodide is not charged at neutral pH (pKa = 6.4,
Barbieri et al. (1987)) and thus does not fulfill the
requirements of the ideal modulator.
The ability of the various anthracycline analogs to increase
DNR accumulation in EHR2/DNR + cells correlated well
with their degree of lipid solubility (Friche et al., 1990a), but
a similar correlation between lipophilicity and inhibition of
photolabelling of Pgp by neither ['251I]iodomycin nor [3H]AZP
could be demonstrated. Neither could a correlation between
the influence of the anthracyclines on DNR accumulation
and inhibition of labelling of Pgp be shown. Yet our data
suggest that lipophilicity plays a decisive role in the disrup-
tion of Pgp function in agreement with Zamora et al. (1988),
Yang et al., 1989, Hofsli & Nissen-Meyer (1990), Wadler &
Yang (1991), and Beck & Qian (1992). Thus aclacinomycin
A, AD-198, and N,N-dibenzyl-DNR, all with an O/W parti-
tion coefficient >200, exercised the most pronounced
inhibitory effect on labelling of Pgp by both [125I] iodomycin
and [3H]AZP. This result prompted us to examine the lipid
solvents, Cremophor EL and Tween 80, that presumably do
not have specific binding sites in Pgp, and we found that the
lipid solvents also show concentration-dependent inhibition
of ['251]iodomycin binding to Pgp with >90% inhibition at
30 jLgml-'. A possible explanation for this inhibitory effect
of the solvents on ['251]iodomycin photolabelling of Pgp
might be that they disturb the lipid bilayer and thereby exert
an indirect effect on ligand binding to Pgp in the membrane.
These results indicate a possible detergent effect of the most
lipophilic anthracyclines (Burke et al., 1989).
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sites on Pgp. We find that when EHR2/DNR + cells are
labelled with ['251I]iodomycin in the presence of a 500-fold
molar excess of AZP, the photolabelling ofPgp is reduced by
only 50% despite the fact that AZP is highly lipid soluble,
with an oil:water partitioning coefficient of >25. This might
indicate that [3H]AZP and ['25I]iodomycin label Pgp at diffe-
rent binding sites or with different binding affinities.
Reported Kd values for binding of [251I]iodomycin and
[3H]AZP to Pgp are 0.025 !iM (Busche et al., 1989b) and 1 jaM
(Safa et al., 1987), respectively. In contrast to the results with
AZP, VCR is found to be a surprisingly good inhibitor of
iodomycin labelling of Pgp despite having a very low
oil:water partition coefficient (1.98), which is in agreement
with data from Beck & Qian (1992) who demonstrate that
the Vinca alkaloid vinblastine competes more effectively than
daunorubicin for [3H]-N-azido-benzoyldaunomycin binding
to Pgp. This suggests that anthracyclines and Vinca alkaloids
might recognize a common area in Pgp.
Our data indicate that the binding site(s) for
[251I]iodomycin and [3H]AZP in Pgp interact with several
anthracycline analogs as well as VCR and MDR modulators.
There appears to be no simple relationship between this
interaction and the ability of the compounds to increase
cellular DNR accumulation. The question is whether there
are several distinct drug binding sites of Pgp, or if a single
multidrug binding site with low specificity exists on this
protein and its lipid environment. Up to now there have been
reports that azidopine and azido-prazosin bind to peptides in
the carboxy terminus of Pgp (Yoshimura et al., 1989; Safa et
al., 1990; Greenberger et al., 1991), that Pgp has two
photoaffinity drug binding sites, one in each half of the
protein (Greenberger et al. 1991), and that AZP non-
competitively inhibits the binding of vinblastine and cyclos-
porin A to Pgp (Tamai & Safa, 1991).
Two caveats in interpreting our results relate to the facts,
that, firstly we have not examined specific reversible binding
of iodomycin or azidopine or carried out saturation
experiments; and, secondly that there is not always a correla-
tion between MDR reversal ability of different drugs and
their lack of binding inhibition, or activity as substrates for
Pgp (Yang et al., 1989; Fleming et al., 1992) as also reported
here. Such results may reflect the possibility that these
experiments were not always done under optimal conditions.
However, given these caveats, we find that the conditions we
chose allowed us to determine the relative ability of a partic-
ular class of compounds (in this case the anthracyclines) to
compete with these radioactive labelled compounds. We
believe that these probes can be used as first screening tools
especially for a single class of drugs to obtain a preliminary
indication as to whether the drugs might be substrates for
Pgp.
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